CD7 Nanobody-Based Immuno-Nanotoxin for Targeted Treatment of T-Cell Acute Lymphoblastic Leukemia
Y Dong, F You, Y Zhang, H Sun, R Cheng… - ACS Applied Nano …, 2024 - ACS Publications
T-cell acute lymphoblastic leukemia (T-ALL) has been plagued by high relapse and mortality
rates due to the lack of available targeted treatment options in the clinic. Herein, a CD7 …
rates due to the lack of available targeted treatment options in the clinic. Herein, a CD7 …
Approach to Older Adults with Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia
S Shimony, MR Luskin - Clinical Lymphoma Myeloma and Leukemia, 2023 - Elsevier
Abstract Philadelphia-chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL)
has historically been associated with poor outcomes in older patients due to adverse …
has historically been associated with poor outcomes in older patients due to adverse …
Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-cell Acute Lymphoblastic Leukemia
JS Braish, E Kugler, E Jabbour, K Woodman… - … Myeloma and Leukemia, 2024 - Elsevier
Background Nelarabine is a purine analog with demonstrated efficacy in the treatment of T-
cell Lymphoblastic Leukemia and Lymphoma (T-ALL/LBL). Despite its efficacy and excellent …
cell Lymphoblastic Leukemia and Lymphoma (T-ALL/LBL). Despite its efficacy and excellent …